Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Meta-Analysis
. 2006;1(3):261-6.
doi: 10.2147/copd.2006.1.3.261.

A meta-analysis on the efficacy of oral theophylline in patients with stable COPD

Néstor A Molfino  1 , Peter Zhang
Affiliations
Meta-Analysis

A meta-analysis on the efficacy of oral theophylline in patients with stable COPD

Néstor A Molfino et al. Int J Chron Obstruct Pulmon Dis. 2006.

Abstract

Background: Theophylline is a nonspecific inhibitor of phosphodiesterases that, despite exerting bronchodilator and anti-inflammatory effects, is a third-line therapy rarely used to treat chronic airflow limitation. We wished to evaluate the efficacy of oral theophylline as measured by improvements in trough (pre-dose) or peak (post-dose) FEV1 and FVC in patients with clinically stable COPD.

Design: Meta-analysis of randomized, placebo-controlled trials reported as of June 2005 in which theophylline was orally administered to stable COPD patients and the functional evaluations included pre- and post-theophylline values for FEV1 and FVC.

Results: Atotal of 18 trials were included in the meta-analysis. The weighted mean differences (WMD) with 95% confidence intervals (95% CI) for improvement over placebo in trough FEV1 and FVC were 0.108L (0.053-0.163) and 0.186L (0.036-0.336), respectively, while peak FEV1 and FVC improved by 0.096L (0.044-0.147) and 0.242L (0.11-0.374), respectively.

Conclusions: Treatment with oral theophylline improves both trough and peak FEV1 and FVC in clinically stable COPD patients. These results support previously reported benefits of theophylline in COPD.

PubMed Disclaimer

Figures

Figure 1
Figure 1
Meta-analysis on trough FEV1 showing results favoring theophylline.
Figure 2
Figure 2
Meta-analysis on trough FVC showing results favoring theophylline.
Figure 3
Figure 3
Meta-analysis on peak FEV1 showing results favoring theophylline.
Figure 4
Figure 4
Meta-analysis on peak FVC showing results favoring theophylline.
See this image and copyright information in PMC

References

    1. Alexander MR, Dull WL, Kasik JE. Treatment of chronic obstructive pulmonary disease with orally administered theophylline. A double-blind, controlled study. JAMA. 1980;244:2286–90. - PubMed
    1. Anderson G, Peel ET, Pardoe T, et al. Sustained-release theophylline in chronic bronchitis. Br J Dis Chest. 1982;76:261–5. - PubMed
    1. Barnes PJ, Adcock IM, Ito K. Histone acetylation and deacetylation: importance in inflammatory lung diseases. Eur Respir J. 2005;25:552–63. - PubMed
    1. Barnes PJ. Theophylline: new perspectives for an old drug. Am J Respir Crit Care Med. 2003;167:813–18. - PubMed
    1. Bellia V, Foresi A, Bianco S, et al. Efficacy and safety of oxitropium bromide, theophylline and their combination in COPD patients: a double-blind, randomized, multicentre study (BREATH Trial) Respir Med. 2002;96:881–9. - PubMed

Publication types